Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Oct 26, 2024; 16(10): 854-859
Published online Oct 26, 2024. doi: 10.4252/wjsc.v16.i10.854
Enhancing the functionality of mesenchymal stem cells: An attractive treatment strategy for metabolic dysfunction-associated steatotic liver disease?
Xiao-Qian Shan, Lan Zhao
Xiao-Qian Shan, Lan Zhao, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China
Author contributions: Shan XQ contributed to the conceptualization, writing-review and editing; Zhao L participated in the supervision of this manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lan Zhao, MD, PhD, Professor, Researcher, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, No. 88 Changling Road, Xiqing District, Tianjin 300381, China. lanzhao69@163.com
Received: July 21, 2024
Revised: September 6, 2024
Accepted: October 8, 2024
Published online: October 26, 2024
Processing time: 95 Days and 10.6 Hours
Abstract

The intrinsic heterogeneity of metabolic dysfunction-associated fatty liver disease (MASLD) and the intricate pathogenesis have impeded the advancement and clinical implementation of therapeutic interventions, underscoring the critical demand for novel treatments. A recent publication by Li et al proposes mesenchymal stem cells as promising effectors for the treatment of MASLD. This editorial is a continuum of the article published by Jiang et al which focuses on the significance of strategies to enhance the functionality of mesenchymal stem cells to improve efficacy in curing MASLD, including physical pretreatment, drug or chemical pretreatment, pretreatment with bioactive substances, and genetic engineering.

Keywords: Metabolic dysfunction-associated fatty liver disease; Mesenchymal stem cells; Preprocess; Cell survival; Therapeutic strategy

Core Tip: Metabolic dysfunction-associated fatty liver disease is a serious health challenge, and new therapies are urgently needed. Jiang et al proposed mesenchymal stem cells as a promising therapeutic approach for metabolic dysfunction-associated fatty liver disease, emphasizing the targeting of key molecular pathways such as glycolipid metabolism, inflammation, oxidative stress, endoplasmic reticulum stress, and fibrosis. This paper concurs this opinion and further discusses some strategies enhance functionality mesenchymal stem cells.